Bruker Co. (NASDAQ:BRKR) Shares Purchased by Ameritas Investment Partners Inc.

Ameritas Investment Partners Inc. boosted its stake in Bruker Co. (NASDAQ:BRKR) by 0.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,911 shares of the medical research company’s stock after buying an additional 235 shares during the quarter. Ameritas Investment Partners Inc.’s holdings in Bruker were worth $1,972,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. First Horizon Advisors Inc. boosted its stake in shares of Bruker by 120.4% in the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after acquiring an additional 218 shares during the last quarter. Rise Advisors LLC acquired a new stake in Bruker during the 1st quarter worth $27,000. Neo Ivy Capital Management purchased a new stake in shares of Bruker during the fourth quarter worth $30,000. Covestor Ltd grew its holdings in shares of Bruker by 139.1% during the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock worth $34,000 after buying an additional 210 shares in the last quarter. Finally, Principal Securities Inc. purchased a new position in shares of Bruker in the fourth quarter worth about $42,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Stock Performance

NASDAQ BRKR opened at $67.54 on Friday. The stock has a fifty day simple moving average of $64.56 and a 200-day simple moving average of $72.76. The company has a current ratio of 1.65, a quick ratio of 0.75 and a debt-to-equity ratio of 1.18. The stock has a market cap of $9.82 billion, a PE ratio of 24.56, a P/E/G ratio of 2.31 and a beta of 1.18. Bruker Co. has a twelve month low of $53.79 and a twelve month high of $94.86.

Bruker (NASDAQ:BRKR) last announced its earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share for the quarter, hitting the consensus estimate of $0.52. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The company had revenue of $800.70 million during the quarter, compared to analyst estimates of $799.44 million. During the same quarter last year, the firm posted $0.50 earnings per share. Bruker’s revenue was up 17.4% compared to the same quarter last year. Equities analysts anticipate that Bruker Co. will post 2.61 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Monday, September 2nd were given a dividend of $0.05 per share. The ex-dividend date was Friday, August 30th. This represents a $0.20 annualized dividend and a dividend yield of 0.30%. Bruker’s dividend payout ratio is currently 7.27%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on BRKR shares. The Goldman Sachs Group dropped their price objective on shares of Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research note on Tuesday, July 9th. Jefferies Financial Group started coverage on Bruker in a research report on Monday, June 3rd. They issued a “buy” rating and a $85.00 price target for the company. Wells Fargo & Company began coverage on Bruker in a research report on Tuesday, August 27th. They set an “overweight” rating and a $78.00 price objective on the stock. Citigroup lowered their price objective on Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday, July 10th. Finally, TD Cowen cut their target price on Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $81.40.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.